An impotence drug whose effects last longer than Viagra has just completed its clinical trials and will be licensed for use in Europe in two months' time. Tadalafil, which is now being tested to ...

White matter hyperintensities and reduced cerebral blood flow are hallmarks of cerebral small vessel disease (CSVD). We tested the feasibility of daily treatment with the vasoactive drug tadalafil in ...

Hitendra R Patel; Dapo Ilo; Nimish Shah; Béatrice Cuzin; David Chadwick; Robert Andrianne; Carsten Henneges; Jane Barry; Katja Hell-Momeni; Julia Branicka; Hartwig ...

Background This multicenter, randomized, double-blind, double-dummy, placebo-controlled trial primarily evaluated the efficacy of tadalafil once-daily (OaD) or on-demand ("pro-re-nata"; PRN) treatment ...

Our objective was to understand the out-of-pocket annual costs of phosphodiesterase-5 (PDE5) inhibitors to treat erectile dysfunction (ED) through drug coverage programs in the United States. We ...

In a groundbreaking move, the Drug Regulatory Authority of Pakistan (DRAP) has authorized local pharmaceutical companies to manufacture Sildenafil Citrate and Tadalafil tablets for the treatment of ...

Getting a prescription for tadalafil (the active ingredient in brand names Adcirca and Cialis) can be a more complicated experience than many men expect. While Cialis and its generic tadalafil are ...

PASSION was a randomized, double-blind, placebo-controlled trial that evaluated the safety and efficacy of tadalafil in patients with heart failure with preserved ejection fraction (HFpEF) and ...

What is Opsynvi for pulmonary hypertension? Opsynvi (macitentan and tadalafil) is an oral therapy approved in the U.S. for treating adults with pulmonary arterial hypertension (PAH) in World Health ...

Opsynvi is a combination of macitentan, an endothelin receptor antagonist, and tadalafil, a phosphodiesterase 5 inhibitor. The Food and Drug Administration (FDA) has approved Opsynvi ® (macitentan and ...